Deep Track Capital Increases Stake in Bicara Therapeutics to 6.21%

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Bicara Therapeutics Inc. (BCAX). The filing indicates that as of March 31, 2026, the reporting persons beneficially own 4,062,500 shares of Common Stock, representing a 6.21% ownership stake in the company. This position marks an increase from the previously reported 0.0% ownership. The shares are held with shared voting and dispositive power among the reporting entities. David Kroin serves as the Managing Member of the General Partner of the investment adviser, Deep Track Capital, LP, and as a Director for the Master Fund. The filing was made under Rule 13d-1(c), certifying that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The calculation of the ownership percentage is based on 65,467,187 shares outstanding as reported in the issuer's 10-K filed in late March 2026.